MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/rhu.0000000000000584

Медицинская библиотека · Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2017

Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients.

Sari Alper, Guven Denizcan, Armagan Berkan, Erden Abdulsamet, Kalyoncu Umut, Karadag Omer, Apras Bilgen Sule, Ertenli Ihsan, Kiraz Sedat, Akdogan Ali

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

The objective of this study was to report the experience with rituximab treatment in a case series of patients with long-standing systemic sclerosis-associated interstitial lung disease (SSc-ILD).

METHODS

We reviewed the charts of 197 SSc patients. Fourteen patients who received rituximab for SSc-ILD participated in this analysis. Pulmonary function tests, high-resolution thorax computed tomography and modified Rodnan skin scores were evaluated at baseline and end of the follow-up.

RESULTS

Median age was 53.2 years (interquartile range, 46.8-55.5 years), and median disease duration was 9.1 years (interquartile range, 5.1-13.6 years). At the end of median follow-up (15 months), although the median forced vital capacity value increased compared with baseline, the change was not statistically significant (52.5 vs. 58.0, P = 0.065). Forced vital capacity was improved in 4 patients and stabilized in 10 patients. High-resolution computed tomography was stable in 7 patients and worsened in 3 patients. Modified Rodnan skin scores remained stable at the end of follow-up (8.0 vs. 6.0, P = 0.6).

CONCLUSIONS

The improvement or stabilization of pulmonary disease was observed in most SSc patients with longer disease duration and worse pulmonary function. Rituximab might be useful in this patient group who is resistant to conventional immunosuppressive treatments.

Для цитирования: Sari Alper, Guven Denizcan, Armagan Berkan, Erden Abdulsamet, Kalyoncu Umut, Karadag Omer, Apras Bilgen Sule, Ertenli Ihsan, Kiraz Sedat, Akdogan Ali. Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients.. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2017. DOI: 10.1097/rhu.0000000000000584.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.